Overview

Study Investigating Safety, Tolerability, Pharmacokinetics（PK） and Antitumor Activities of Anti-PD-1(Programmed Death-1) Monoclonal Antibody

Status:
Completed

Trial end date:
2020-10-13

Target enrollment:

Participant gender:

Summary

Phase I/II Study investigating safety, tolerability, pharmacokinetics and preliminary antitumor activities of anti-PD-1 monoclonal antibody in Chinese participants with advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BeiGene

Treatments:

Antibodies
Antibodies, Monoclonal